The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
Patients must be diagnosed with hematological neoplasms
Antineoplastic drugs or anti-infective drugs used as part of regular treatment
expected survival time less than the treatment cycle;
patients with other factors that researcher considers unsuitable for inclusion.
Wei Zhao
Lead sponsor
Shandong University
Sponsor institution
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborator